Recombinant Human Integrin alpha 10 beta 1 Protein, CF

• Reactivity: Hu
• Applications: Binding Activity
• Format: Carrier-Free

Recombinant Human Integrin alpha 10 beta 1 Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Mouse Laminin I (Catalog # 3400-010-02) is coated at 10 μg/mL, Recombinant Human Integrin alpha 10 beta 1 binds with an apparent K_d <5 nM.
• Source: Chinese Hamster Ovary cell line, CHO-derived human Integrin alpha 10 beta 1 protein
  

  Human Integrin alpha 10 (Phe23-Ser1122) Accession # O75578	GGGSGGGSGGGS	Acidic Tail	HHHHHH
  Human Integrin beta 1 (Gln21-Asp728) Accession # P05556	GGGSGGGSGGGS	Basic Tail
  N-terminus			C-terminus

• Accession #: O75578 (Integrin alpha 10) & P05556 (Integrin beta 1)
• N-terminal Sequence: Phe23 ( alpha 10) & Gln21 ( beta 1)
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Binding Activity
• Theoretical MW: 128.8 kDa ( alpha 10) & 86.4 kDa ( beta 1).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 160-175 kDa & 125-150 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Integrin alpha 10 beta 1 Protein, CF

• Integrin alpha 10 beta 1

Background

Integrin alpha 10 beta 1 is one of twelve integrin family adhesion receptors that share the beta 1 subunit (1-3). The non-covalent heterodimer of 160 kDa alpha 11 and 130 kDa beta 1/CD29 type I transmembrane glycoprotein subunits is expressed mainly on chondrocytes within cartilage, but also in fibrous connective tissues such as heart valves and ligaments (3, 4). The alpha 10 extracellular domain (ECD) contains an I (inserted) domain which includes the ligand binding site (2, 3, 5). The beta 1 ECD contains a vWFA domain, which participates in binding. Each subunit then has a transmembrane sequence and a short cytoplasmic tail. The dimer is folded when it is least active. Divalent cations and intracellular (inside-out) signaling convert it to its most active, extended and open conformation (1, 2). The 1100 amino acid (aa) human alpha 10 extracellular domain (ECD) shares 88-92% aa sequence identity with mouse, rat, canine and bovine alpha 10, while the 708 aa human beta 1 ECD shares 92‑96% aa sequence identity with rat, bovine, mouse, and feline beta 1. A reported alpha 10 splice variant lacking ECD aa 974-1012 was not expressed on the cell surface (6). I domain-containing beta 1 integrins alpha 1 beta 1, alpha 2 beta 1, alpha 10 beta 1 and alpha 11 beta 1 all bind collagens; all but alpha 11 beta 1 also bind laminins (5, 7, 8). During cartilage differentiation, alpha 10 beta 1 is thought to be the main integrin binding type II and IX cartilage collagens (3‑5, 7-10). However, deletion of mouse alpha 10 causes a mild phenotype including slightly shortened bones and narrowed hypertrophic zones, indicating that another collagen-binding integrin, likely alpha 2 beta 1, may compensate for alpha 10 beta 1 functions (11). Migration of melanoma cells has been noted to correlate with alpha 10 beta 1 expression (12).

1. Takada, Y. et al. (2007) Genome Biol. 8:215.
2. Luo, B-H. et al. (2007) Annu. Rev. Immunol. 25:619.
3. Camper, L. et al. (1998) J. Biol. Chem. 273:20383.
4. Camper, L. et al. (2001) Cell Tiss. Res. 306:107.
5. Tulla, M. et al. (2001) J. Biol. Chem. 276:48206.
6. Bengtsson, T. et al. (2001) Matrix Biol. 20:565.
7. McCall-Culbreath, K.D. and M.M. Zutter (2008) Curr. Drug Targets 9:139.
8. Popova, S.N. et al. (2007) Acta Physiol. 190:179.
9. Varas, L. et al. (2007) Stem Cells Dev. 16:965.
10. Gigout, A. et al. (2008) J. Biol. Chem. 283:31522.
11. Bengtsson, T. et al. (2004) J. Cell Sci. 118:939.
12. Wenke, A.K. et al. (2007) Cell Oncol. 29:373.

Publications for Integrin alpha 10 beta 1 (5895-AB)(1)

Publication using 5895-AB

• Y Cheng, L Xie, Z Xu, M Hao, B Yang, W Shan, Y Wang, Q Lv, X Chen NrCAM secreted by endometrial stromal cells enhances the progestin sensitivity of endometrial cancer cells through epigenetic modulation of PRB Cancer Gene Therapy, 2022-04-06;0(0):. 2022-04-06 [PMID: 35388173] (Bioassay, Human)

Bioinformatics

• Uniprot:
  • O75578 (Integrin alpha 10) & P05556 (Integrin beta 1)()